Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/taylor-francis/melphalan-old-and-new-uses-of-a-still-master-drug-for-multiple-myeloma-m8TJTdSDeb
References (176)
-
A. Beaven, T. Shea (2006)
Palifermin: a keratinocyte growth factor that reduces oral mucositis after stem cell transplant for haematological malignanciesExpert Opinion on Pharmacotherapy, 7
-
H. Ehrsson, S. Eksborg, A. Österborg, H. Mellstedt, A. Lindfors (1989)
Oral melphalan pharmacokinetics — relation to dose in patients with multiple myelomaMedical Oncology and Tumor Pharmacotherapy, 6
-
C. Dumontet, S. Landi, T. Reiman, A. Plesa, I. Bellini, R. Barale, L. Pilarski, S. Tavtigian, T. Perry, F. Gemignani (2006)
Genetic Polymorphisms Correlated with Outcome in Multiple Myeloma Patients Receiving High Dose Melphalan.Blood, 110
-
J. Hernandez, R. García-Sanz, E. Golvano, J. Bladé, J. Fernández-Calvo, J. Trujillo, J. Soler, S. Gardella, F. Carbonell, G. Mateo, J. Miguel (2004)
Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myelomaBritish Journal of Haematology, 127
-
W. Jaksic, S. Trudel, Hong Chang, Y. Trieu, X. Qi, J. Mikhael, D. Reece, Christine Chen, A. Stewart (2005)
Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 28
-
A. Palumbo, I. Avonto, B. Bruno, M. Ambrosini, S. Bringhen, F. Cavallo, P. Falco, M. Boccadoro (2006)
Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myelomaEuropean Journal of Haematology, 76
-
Patrizia Tosi, E. Zamagni, S. Ronconi, M. Benni, Maria Motta, S. Rizzi, S. Tura, Michele Cavo (2000)
Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failureLeukemia, 14
-
B. Barlogie, S. Jagannath, K. Desikan, S. Mattox, D. Vesole, D. Siegel, G. Tricot, Nikhil Munshi, A. Fassas, S. Singhal, J. Mehta, E. Anaissie, D. Dhodapkar, S. Naucke, J. Cromer, J. Sawyer, J. Epstein, D. Spoon, D. Ayers, B. Cheson, J. Crowley (1999)
Total therapy with tandem transplants for newly diagnosed multiple myeloma.Blood, 93 1
-
C. Crawley, S. Iacobelli, B. Björkstrand, J. Apperley, D. Niederwieser, G. Gahrton (2007)
Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning.Blood, 109 8
-
Donna Reece, Christopher Bredeson, W. Pérez, S. Jagannath, Mei-Jie Zhang, K. Ballen, G. Elfenbein, C. Freytes, RobertPeter Gale, Morie Gertz, J. Gibson, S. Giralt, Armand Keating, Robert Kyle, D. Maharaj, Deborah Marcellus, P. McCarthy, G. Milone, S. Nimer, Santiago Pavlovsky, L. To, D. Weisdorf, P. Wiernik, J. Wingard, D. Vesole (2003)
Autologous stem cell transplantation in multiple myeloma patients <60 vs ⩾60 years of ageBone Marrow Transplantation, 32
-
J. Crowley, J. Jacobson, R. Alexanian (2001)
Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience.Seminars in hematology, 38 3
-
R. Alexanian, Meletios Dimopoulos, Terry Smith, K. Delasalle, B. Barlogie, R. Champlin (1994)
Limited value of myeloablative therapy for late multiple myeloma.Blood, 83 2
-
N. Kröger, H. Sayer, R. Schwerdtfeger, M. Kiehl, A. Nagler, H. Renges, T. Zabelina, B. Fehse, F. Ayuk, G. Wittkowsky, N. Schmitz, A. Zander (2002)
Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality.Blood, 100 12
-
S. Pasquali, J. Maqueo, J. Vela, R. Kyle, T. Leong, E. Fritz, S. Suciu, I. Palva, T. Oivanen, C. Corrado, F. Lastiri, D. Peest, O. Kildahl‐Andersen, A. Maniatis, R. Alison, M. Clarke, V. Evans, R. Gray, E. Greaves, E. Hall, C. Hicks, S. James, R. Peto, S. Richards, D. Sinclair, A. Tooth, K. Wheatley, G. Avvisati, M. Boccadoro, R. Bugliosi, F. Mandelli, Petrucci, A. Pileri, M. Tribalto, R. Alexanian, K. Delasalle, J. Child, J. Dunn, I. Maclennan, D. Milligan, H. Mellstedt, A. Osterborg, M. Hjorth, E. Holmberg, S. Rodjer, J. Westin, O. Kamiya, K. Shimizu, D. Bergsagel, C. Shustik, E. Hippe, E. Kjaersgaard, I. Turesson, A. Riccardi, G. Ucci, J. Bladé, M. Fontanillas, L. Rosa, A. Montuoro, A. Bartolucci, G. Omura, M. Stagg, S. Salmon, C. Tangen, P. Jacobs, L. Wood, L. Levy, Grp Mtc. (1998)
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 12
-
C. Weaver, B. Zhen, L. Schwartzberg, R. Leff, M. Magee, L. Geier, K. Deaton, L. Lewkow, C. Buckner (1998)
Phase I–II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myelomaBone Marrow Transplantation, 22
-
G. Phillips, G. Phillips, Barry Meisenberg, D. Reece, V. Adams, A. Badros, J. Brunner, Robert Fenton, J. Filicko, D. Grosso, G. Hale, D. Howard, V. Johnson, A. Kniska, A. Kniska, K. Marshall, R. Nath, E. Reed, E. Reed, Aaron Rapoport, Naoko Takebe, D. Vesole, J. Wagner, Neal Flomenberg (2004)
Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 10 7
-
J. Miguel, J. Lahuerta, Ramón García-Sanz, A. Alegre, J. Bladé, R. Martínez, J. García-Laraña, J. Rubia, A. Sureda, María Vidal, A. Escudero, E. Pérez-Esquiza, E. Conde, J. García-Ruiz, Rafael Cabrera, D. Caballero, J. Moraleda, A. León, J. Besalduch, M. Hernández, J. Rifón, F. Hernández, Carlos Solano, L. Palomera, R. Parody, Juan Gonzalez, R. Mataix, J. Maldonado, J. Constela, D. Carrera, J. Bello, J. Pablos, J. Pérez-Simón, Juan Torres, J. Olanguren, E. Prieto, G. Acebede, M. Penarrubia, P. Torres, J. Díez-Martín, Ana Rivas, Jaime Sánchez, J. Díaz-Mediavilla (2000)
Are myeloma patients with renal failure candidates for autologous stem cell transplantation?The hematology journal : the official journal of the European Haematology Association, 1 1
-
P. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S. Rajkumar, G. Srkalović, M. Alsina, R. Alexanian, David Siegel, R. Orlowski, D. Kuter, S. Limentani, Stephanie Lee, T. Hideshima, D. Esseltine, M. Kauffman, Julian Adams, D. Schenkein, K. Anderson (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma.The New England journal of medicine, 348 26
-
J. Lahuerta, C. Grande, J. Bladé, J. Martínez-López, J. Serna, A. Alegre, J. Laraña, D. Caballero, J. Rubia, Julián Marı´n, C. Pérez-López, A. Sureda, A. Escudero, R. Cabrera, E. Conde, J. García-Ruiz, K. Pérez-Equiza, F. Hernandez, L. Palomera, A. León, P. Giraldo, C. Solano, J. Bargay, J. Miguel (2002)
Myeloablative Treatments for Multiple Myeloma: Update of a Comparative Study of Different Regimens Used in Patients from the Spanish Registry for Transplantation in Multiple MyelomaLeukemia & Lymphoma, 43
-
M. Cavo, P. Tosi, E. Zamagni, C. Cellini, P. Tacchetti, F. Patriarca, F. Raimondo, E. Volpe, S. Ronconi, D. Cangini, F. Narni, A. Carubelli, L. Masini, L. Catalano, M. Fiacchini, A. Vivo, A. Gozzetti, A. Lazzaro, S. Tura, M. Baccarani (2007)
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 17
-
M. Raab, I. Breitkreutz, M. Hundemer, A. Benner, J. Klaus, U. Hegenbart, T. Moehler, A. Ho, M. Zeier, H. Goldschmidt (2006)
The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure.Haematologica, 91 11
-
R. Spielberger, P. Stiff, W. Bensinger, T. Gentile, D. Weisdorf, T. Kewalramani, T. Shea, S. Yanovich, Keith Hansen, S. Noga, J. McCarty, C. Lemaistre, E. Sung, B. Blazar, D. Elhardt, Mon‐Gy Chen, C. Emmanouilides (2017)
Palifermin for oral mucositis after intensive therapy for hematologic cancers -
M. Bishton, M. Gilyead, E. Gupta, C. Williams, N. Russell, J. Byrne (2007)
High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma.Leukemia research, 31 8
-
M. Gertz, M. Lacy, A. Dispenzieri, S. Hayman, Shaji Kumar, N. Leung, D. Gastineau (2007)
Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myelomaBone Marrow Transplantation, 39
-
B. Barlogie, Roy Hall, A. Zander, Karel Dicke, R. Alexanian (1986)
High-dose melphalan with autologous bone marrow transplantation for multiple myeloma.Blood, 67 5
-
T. Mcelwain, R. Powles (1983)
HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMAThe Lancet, 322
-
W. Sperr, K. Lechner, I. Pabinger (2007)
Rituximab for the treatment of acquired antibodies to factor VIII.Haematologica, 92 1
-
Pick Ai, Schoenfeld (1948)
THE TREATMENT OF MULTIPLE MYELOMAMedical Journal of Australia, 1
-
A. Badros, B. Barlogie, E. Siegel, C. Morris, R. Desikan, M. Zangari, A. Fassas, E. Anaissie, N. Munshi, G. Tricot (2001)
Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 yearsBritish Journal of Haematology, 114
-
A. Palumbo, A. Bertola, P. Musto, T. Caravita, V. Callea, M. Nunzi, M. Grasso, P. Falco, C. Cangialosi, M. Boccadoro (2005)
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myelomaCancer, 104
-
M. Pineda‐Roman, Michelle Fox, K. Hollmig, E. Anaissie, F. Rhee, G. Tricot, M. Zangari, A. Mohiuddin, B. Barlogie (2006)
Retrospective Analysis of Fractionated High-Dose Melphalan (F-MEL) and Bortezomib-Thalidomide-Dexamethasone (VTD) with Autotransplant (AT) Support for Advanced and Refractory Multiple Myeloma (AR-MM).Blood, 108
-
B. Barlogie, R. Alexanian, K. Dicke, G. Zagars, G. Spitzer, S. Jagannath, L. Horwitz (1987)
High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myelomaBlood, 70
-
R. Alexanian, D. Bergsagel, P. Migliore, W. Vaughn, C. Howe (1968)
Melphalan therapy for plasma cell myeloma.Blood, 31 1
-
J. Semple, Rukhsana Aslam, Michael Kim, E. Speck, D. Stewart, Erik Weirsma, J. Freedman, M. Kjaersgaard (2006)
The Specificity and Isotype of Monoclonal Anti-D Antibodies Dictates Their Ability To Inhibit Opsonized Platelet Phagocytosis.Blood, 108
-
Esa Jantunen, T. Kuittinen, K. Penttilä, P. Lehtonen, E. Mahlamäki, T. Nousiainen (2006)
High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (⩾65 years) myeloma patients: comparison with younger patients treated on the same protocolBone Marrow Transplantation, 37
-
B. Hoogstraten, P. Sheehe, J. Cuttner, T. Cooper, R. Kyle, R. Oberfield, S. Townsend, J. Harley, D. Hayes, G. Costa, J. Holland (1967)
Melphalan in multiple myeloma.Blood, 30 1
-
A. Palumbo, S. Bringhen, M. Petrucci, P. Musto, F. Rossini, M. Nunzi, V. Lauta, C. Bergonzi, A. Barbui, T. Caravita, A. Capaldi, P. Pregno, T. Guglielmelli, M. Grasso, V. Callea, A. Bertola, F. Cavallo, P. Falco, C. Rus, M. Massaia, F. Mandelli, A. Carella, E. Pogliani, A. Liberati, F. Dammacco, G. Ciccone, M. Boccadoro (2004)
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial.Blood, 104 10
-
R. Kyle, T. Leong, Shuli Li, M. Oken, N. Kay, B. Ness, P. Greipp (2006)
Complete response in multiple myelomaCancer, 106
-
C. Segeren, P. Sonneveld, B. Holt, E. Vellenga, A. Croockewit, G. Verhoef, J. Cornelissen, M. Schaafsma, M. Oers, P. Wijermans, W. Fibbe, S. Wittebol, H. Schouten, M. Kooy, D. Biesma, J. Baars, R. Slater, Monique Steijaert, I. Buijt, H. Lokhorst (2002)
Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.Blood, 101 6
-
J. Rubia, J. Bladé, J. Lahuerta, J. Ribera, R. Martínez, A. Alegre, J. García-Laraña, P. Fernández, A. Sureda, F. Arriba, D. Carrera, J. Besalduch, R. Boyero, L. Bernal, M. Hernandez, P. García, J. Pérez-Calvo, A. Alcalá, L. Casado, J. Miguel (2006)
Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.Haematologica, 91 5
-
E-mail: [email protected] -
Dorothy Keefe, Mark Schubert, L. Elting, Stephen Sonis, Joel Epstein, J. Raber-Durlacher, C. Migliorati, Deborah McGuire, Ronald Hutchins, Douglas Peterson (2007)
Clinical Practice Guidelines for the Prevention and Treatment of Mucositis -
A. Palumbo, M. Ambrosini, G. Benevolo, P. Pregno, N. Pescosta, V. Callea, C. Cangialosi, T. Caravita, F. Morabito, P. Musto, S. Bringhen, P. Falco, I. Avonto, F. Cavallo, M. Boccadoro (2007)
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.Blood, 109 7
-
B. Björkstrand, P. Ljungman, J. Bird, D. Samson, Gösta Gahrton (1995)
Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma.Bone marrow transplantation, 15 3
-
(2007)
Velcade and high dose melphalan: a new preparative regimen -
I. Ghobrial, X. Leleu, E. Hatjiharissi, T. Hideshima, C. Mitsiades, R. Schlossman, K. Anderson, P. Richardson (2007)
Emerging drugs in multiple myelomaExpert Opinion on Emerging Drugs, 12
-
A. Palumbo, S. Triolo, C. Argentino, S. Bringhen, A. Dominietto, C. Rus, P. Omedè, C. Tarella, A. Pileri, M. Boccadoro (2016)
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Dose-Intensive Melphalan With Stem Cell Support (MEL100) Is Superior to Standard Treatment in Elderly Myeloma Patients -
B. Barlogie, G. Tricot, E. Rasmussen, E. Anaissie, F. Rhee, M. Zangari, A. Fassas, K. Hollmig, M. Pineda‐Roman, J. Shaughnessy, J. Epstein, J. Crowley (2006)
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.Blood, 107 7
-
M. Qazilbash, R. Saliba, C. Hosing, F. Mendoza, S. Qureshi, D. Weber, Michael Wang, Thuy Flosser, D. Couriel, M. Lima, P. Kebriaei, U. Popat, A. Alousi, R. Champlin, S. Giralt (2007)
Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myelomaBone Marrow Transplantation, 39
-
M. Mateos, J. Hernández, M. Hernandez, N. Gutiérrez, L. Palomera, M. Fuertes, J. Díaz-Mediavilla, J. Lahuerta, J. Rubia, M. Terol, A. Sureda, J. Bargay, P. Ribas, F. Arriba, A. Alegre, A. Oriol, D. Carrera, J. García-Laraña, R. García-Sanz, J. Bladé, F. Prósper, G. Mateo, D. Esseltine, H. Velde, J. Miguel (2006)
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.Blood, 108 7
-
K. Lilleby, P. García, T. Gooley, P. McDonnnell, R. Taber, L. Holmberg, D. Maloney, O. Press, W. Bensinger (2006)
A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantationBone Marrow Transplantation, 37
-
(2007)
Website Papers of special notes have been highlighted as either of interest ( • ) or of considerable interest ( • • ) to readers -
K. Shide, K. Shimoda, K. Kamezaki, Haruko Kakumitsu, T. Kumano, A. Numata, F. Ishikawa, K. Takenaka, Ken Yamamoto, T. Matsuda, M. Harada (2006)
Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence.Leukemia research, 31 8
-
David Cunningham, L. Paz-Ares, S. Milan, R. Powles, Marianne Nicolson, T. Hickish, Peter Selby, J. Treleavan, C. Viner, J. Malpas (1994)
High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 4
-
Harrosseau Jl (2007)
Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up.Annals of Oncology, 18
-
S. Bringhen, I. Avonto, V. Magarotto, M. Boccadoro, A. Palumbo (2006)
Investigational treatments for multiple myelomaExpert Opinion on Investigational Drugs, 15
-
V. Roy, Bergsagel Leif, A. Jacob, Greipp Philip (2006)
Melphalan (M), Prednisone (P) and Lenalidomide (R) Combination (MPR) for Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation.Blood, 108
-
N. Kröger, R. Schwerdtfeger, M. Kiehl, H. Sayer, H. Renges, T. Zabelina, B. Fehse, F. Tögel, G. Wittkowsky, R. Kuse, A. Zander (2002)
Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma.Blood, 100 3
-
Affi liation -
M. Pineda‐Roman, G. Tricot (2007)
High-dose therapy in patients with plasma cell dyscrasias and renal dysfunction.Contributions to nephrology, 153
-
A. Bosanquet, E. Gilby (1982)
Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma.European journal of cancer & clinical oncology, 18 4
-
J. Berenson, R. Boccia, D. Siegel, M. Bozdech, A. Bessudo, E. Stadtmauer, J. Pomeroy, R. Steis, M. Flam, J. Lutzky, S. Jilani, J. Volk, Siu-Fun Wong, R. Moss, Ravi Patel, D. Ferretti, K. Russell, R. Louie, H. Yeh, R. Swift (2006)
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single‐arm studyBritish Journal of Haematology, 135
-
J. Lahuerta, C. Grande, J. Martínez-López, J. Serna, R. Toscano, M. Ortiz, S. Larregla, E. Conde, A. Insunza, J. Miguel, J. Bargay, R. Cabrera, J. García-Ruiz, C. Albó, L. García-Alonso, F. Solano, P. Vivancos, A. León, J. Miguel (2003)
Tandem transplants with different high‐dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula Ósea phase II trialBritish Journal of Haematology, 120
-
A. Palumbo, S. Bringhen, A. Bertola, F. Cavallo, P. Falco, M. Massaia, B. Bruno, C. Rus, A. Barbui, T. Caravita, P. Musto, N. Pescosta, F. Rossini, M. Vignetti, M. Boccadoro (2004)
Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)Leukemia, 18
-
R. Comenzo, H. Hassoun, T. Kewalramani, V. Klimek, M. Dhodapkar, M. Dhodapkar, L. Reich, J. Teruya-Feldstein, Martin Fleisher, Daniel Filippa, Stephen Nimer (2006)
Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantationLeukemia, 20
-
M. Attal, J. Harousseau, A. Stoppa, J. Sotto, J. Fuzibet, J. Rossi, P. Casassus, H. Maisonneuve, T. Facon, N. Ifrah, C. Payen, R. Bataille (1996)
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaThe New England Journal of Medicine, 335
-
(2007)
Matched pair analysis of intravenous busulfan and melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation -
S. Lenhoff, M. Hjorth, E. Holmberg, I. Turesson, J. Westin, J. Nielsen, F. Wisløff, L. Brinch, K. Carlson, Margaretha Carlsson, I. Dahl, P. Gimsing, E. Hippe, H. Johnsen, J. Lamvik, E. Löfvenberg, I. Nesthus, S. Rödjer (2000)
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.Blood, 95 1
-
• A concise and updated description of the stem cell transplant procedures for the treatment of MM -
J. Fernberg, B. Johansson, R. Lewensohn, H. Mellstedt (1990)
Oral dosage of melphalan and response to treatment in multiple myeloma.European journal of cancer, 26 3
-
E. Terpos, A. Anagnostopoulos, D. Heath, E. Kastritis, D. Christoulas, N. Anagnostopoulos, M. Roussou, K. Tsionos, P. Croucher, M. Dimopoulos (2006)
The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1α and Angiogenic Cytokines.Blood, 108
-
K. Zervas, A. Pouli, B. Gregoraki, N. Anagnostopoulos, M. Dimopoulos, K. Bourantas, M. Tzilianos, D. Barbarousi, E. Venetis, N. Vyniou, A. Maniatis (2001)
Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon‐α with melphalan and prednisone (MP) and interferon‐α (IFN‐α) in patients with good‐prognosis multiple myeloma: a prospective randomized studyEuropean Journal of Haematology, 66
-
S. Fukuda, K. Sunami, T. Sezaki (1999)
[Stem cell transplantation in multiple myeloma].Gan to kagaku ryoho. Cancer & chemotherapy, 26 10
-
J. Harrosseau (2007)
Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 18 Suppl 2
-
A. Palumbo, C. Rus, D. Rossi, P. Pregno, M. Ambrosini, I. Avonto, F. Cavallo, M. Iacobelli, G. Gaidano, C. Mitsiades, P. Richardson, K. Anderson, M. Boccadoro (2006)
A Multi-Center Phase I/II Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Avanced Multiple Myeloma Patients.Blood, 108
-
M. Attal, J. Harousseau, T. Facon, F. Guilhot, C. Doyen, J. Fuzibet, M. Monconduit, C. Hulin, D. Caillot, R. Bouabdallah, L. Voillat, J. Sotto, B. Grosbois, R. Bataille (2003)
Single versus double autologous stem-cell transplantation for multiple myeloma.The New England journal of medicine, 349 26
-
(2006)
• The fi rst large trial demonstrating the usefulness of thalidomide as a maintenance therapy after SCT in selected patients -
A. Christoforidou, R. Saliba, Patricia Williams, M. Qazilbash, L. Roden, A. Alemán, D. Weber, F. Mendoza, D. Podoloff, R. Wendt, H. Breitz, R. Alexanian, R. Champlin, S. Giralt (2007)
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 13 5
-
M. Kassar, E. Medoff, S. Seropian, Dennis Cooper (2007)
Outpatient high‐dose melphalan in multiple myeloma patientsTransfusion, 47
-
L. Trentin, L. Terrin, M. Degan, I. Corradini, N. Maschio, Enrica Rampazzo, E. Boscaro, R. Bertorelle, P. Carli, M. Bo, G. Binotto, Gattei, G. Semenzato, A. Rossi (2007)
Telomerase as a new prognostic factor in B-cell chronic lymphocytic leukemiaHaematologica, 92
-
S. Acharya, R. Schloss, J. Dyke, A. Narang, D. Mintz, R. Adler, D. DiMichele (2006)
Power Doppler Sonography Is a Promising Imaging Tool in the Diagnosis of Hemophilic Synovitis - Preliminary Analyses.Blood, 108
-
D. Garwicz, Andreas Lennartsson, S. Jacobsen, U. Gullberg, A. Lindmark (2005)
Biosynthetic profiles of neutrophil serine proteases in a human bone marrow-derived cellular myeloid differentiation model.Haematologica, 90 1
-
R. Alexanian, M. Dimopoulos, Jeane Hester, K. Delasalle, R. Champlin (1994)
Early myeloablative therapy for multiple myeloma.Blood, 84 12
-
B. Barlogie, S. Jagannath, D. Vesole, S. Naucke, B. Cheson, S. Mattox, D. Bracy, S. Salmon, J. Jacobson, J. Crowley, G. Tricot (1997)
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.Blood, 89 3
-
S. Kristinsson, O. Landgren, P. Dickman, A. Derolf, M. Björkholm (2007)
Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 15
-
P. Zhou, Yana Zhang, C. Martínez, N. Kalakonda, S. Nimer, R. Comenzo (2003)
Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination.Blood, 102 2
-
P. Moreau, N. Milpied, B. Mahé, N. Juge-Morineau, M. Rapp, Régis Bataille, J. Harousseau (1999)
Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myelomaBone Marrow Transplantation, 23
-
S. Crary, Heidi Orden, J. Journeycake (2006)
Experience with Intravenous Enoxaparin in Critically Ill Infants and Children.Blood, 108
-
C. Vigneau, C. Ardiet, M. Bret, M. Laville, D. Fiére, B. Tranchand, D. Fouque (2002)
Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.Journal of nephrology, 15 6
-
W. Gregory, M. Richards, J. Malpas (1992)
Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 2
-
R. Alexanian, M. Dimopoulos, K. Delasalle, B. Barlogie (1992)
Primary dexamethasone treatment of multiple myeloma.Blood, 80 4
-
L. Knudsen, B. Nielsen, P. Gimsing, C. Geisler (2005)
Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failureEuropean Journal of Haematology, 75
-
O. Cope, S. Wyman (1948)
Multiple myeloma.The New England journal of medicine, 239 10
-
A. Palumbo, I. Avonto, B. Bruno, A. Falcone, P. Scalzulli, M. Ambrosini, S. Bringhen, F. Gay, C. Rus, F. Cavallo, P. Falco, M. Massaia, P. Musto, M. Boccadoro (2006)
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.Clinical lymphoma & myeloma, 6 6
-
R. Orlowski (2006)
Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantation.Hematology. American Society of Hematology. Education Program
-
(2005)
Single versus double high dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial -
M. Dimopoulos, V. Souliotis, A. Anagnostopoulos, C. Papadimitriou, P. Sfikakis (2005)
Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 19
-
P. Moreau, Cyrille Hullin, F. Garban, I. Yakoub-Agha, L. Benboubker, M. Attal, G. Marit, J. Fuzibet, C. Doyen, L. Voillat, C. Berthou, N. Ketterer, P. Casassus, M. Monconduit, M. Michallet, A. Najman, J. Sotto, R. Bataille, J. Harousseau (2006)
Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol.Blood, 107 1
-
M. Cavo, M. Benni, S. Ronconi, M. Fiacchini, A. Gozzetti, E. Zamagni, C. Cellini, P. Tosi, M. Baccarani, S. Tura (2002)
Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.Haematologica, 87 9
-
M. Dimopoulos, V. Souliotis, A. Anagnostopoulos, C. Bamia, A. Pouli, I. Baltadakis, E. Terpos, S. Kyrtopoulos, P. Sfikakis (2006)
Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myelomaHaematologica, 92
-
B. Björkstrand (2001)
European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma.Seminars in hematology, 38 3
-
D. O’Shea, C. Giles, E. Terpos, J. Perz, M. Politou, V. Sana, K. Naresh, I. Lampert, D. Samson, S. Narat, E. Kanfer, E. Olavarría, J. Apperley, A. Rahemtulla (2006)
Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patientsBone Marrow Transplantation, 37
-
B. Barlogie, G. Tricot, F. Rhee, E. Angtuaco, R. Walker, J. Epstein, J. Shaughnessy, S. Jagannath, V. Bolejack, Jennifer Gurley, A. Hoering, D. Vesole, R. Desikan, D. Siegel, J. Mehta, S. Singhal, N. Munshi, M. Dhodapkar, Bonnie Jenkins, M. Attal, J. Harousseau, J. Crowley (2006)
Long‐term outcome results of the first tandem autotransplant trial for multiple myelomaBritish Journal of Haematology, 135
-
A. Palumbo, P. Falco, P. Corradini, A. Falcone, F. Raimondo, N. Giuliani, C. Crippa, G. Ciccone, P. Omedè, M. Ambrosini, F. Gay, S. Bringhen, P. Musto, R. Foà, R. Knight, J. Zeldis, M. Boccadoro, M. Petrucci (2007)
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 28
-
S. Capria, M. Petrucci, A. Pulsoni, M. Ribersani, E. Baldacci, M. Propris, G. Meloni (2006)
High-Dose Idarubicin, Busulphan and Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma Responsive to DAV Chemotherapy: Comparison with a Historical ControlActa Haematologica, 115
-
A. Pulsoni, Nicoletta Villivà, E. Cavalieri, P. Falcucci, G. Verde, R. Matera, M. Petrucci, M. Tosti, F. Mandelli (2002)
Continuous Low Dose of Melphalan and Prednisone in Patients with Multiple Myeloma of Very Old Age or Severe Associated DiseaseDrugs & Aging, 19
-
P. Moreau, J. Harousseau, J. Wijdenes, N. Morineau, N. Milpied, R. Bataille (2000)
A combination of anti‐interleukin 6 murine monoclonal antibody with dexamethasone and high‐dose melphalan induces high complete response rates in advanced multiple myelomaBritish Journal of Haematology, 109
-
F. Garban, M. Attal, M. Michallet, C. Hulin, J. Bourhis, I. Yakoub-Agha, T. Lamy, G. Marit, F. Maloisel, C. Berthou, M. Dib, D. Caillot, B. Deprijck, N. Ketterer, J. Harousseau, J. Sotto (2005)
Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple -
J. Wong, G. Somlo, R. Spielberger, S. Forman, L. Poppelwell, T. Schultheiss, P. Frankel, A. Krishnan, F. Sahebi, P. Parker (2007)
Phase I trial of escalating doses of total marrow irradiation (TMI) with helical tomotherapy and peripheral blood progenitor cell rescue (PBPC) following high-dose melphalan and PBPC as part of tandem high-dose therapy (THDT) for patients with multiple myeloma (MM)Journal of Clinical Oncology, 25
-
Esa Jantunen (2006)
Autologous stem cell transplantation beyond 60 years of ageBone Marrow Transplantation, 38
-
J. Bird, Rhian Fuge, B. Sirohi, J. Apperley, A. Hunter, J. Snowden, P. Mahendra, D. Milligan, J. Byrne, T. Littlewood, C. Fegan, G. McQuaker, A. Pagliuca, P. Johnson, A. Rahemtulla, Curly Morris, D. Marks (2006)
The clinical outcome and toxicity of high‐dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation studyBritish Journal of Haematology, 134
-
S. Giralt, W. Bensinger, M. Goodman, D. Podoloff, J. Eary, R. Wendt, R. Alexanian, D. Weber, D. Maloney, L. Holmberg, Joseph Rajandran, H. Breitz, R. Ghalie, R. Champlin (2003)
166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials.Blood, 102 7
-
M. Dimopoulos, A. Anagnostopoulos, E. Terpos, Panagiotis Repoussis, A. Zomas, E. Katodritou, M. Kyrtsonis, Souzana Delibasi, A. Vassou, A. Pouli, K. Zervas, N. Anagnostopoulos, A. Maniatis (2006)
Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma.Haematologica, 91 2
-
E. Osgood (1960)
The survival time of patients with plasmocytic myeloma.Cancer chemotherapy reports, 9
-
Choon-kee Lee, A. Badros, B. Barlogie, C. Morris, M. Zangari, A. Fassas, F. Rhee, M. Cottler-Fox, J. Jacobson, R. Thertulien, F. Muwalla, S. Mazher, E. Anaissie, G. Tricot (2003)
Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.Experimental hematology, 31 1
-
M. Qazilbash, R. Saliba, M. Davis, F. Mendoza, C. Hosing, D. Couriel, M. Lima, P. Kebriaei, D. Weber, Michael Wang, A. Alousi, S. Matthes, Roy Jones, R. Champlin, S. Giralt (2006)
Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.Blood, 108
-
• The most recent guidelines for the management of MM -
R. García-Sanz, J. Hernández, A. Sureda, J. García-Laraña, Felipe Prosper, A. Alegre, A. Bárez, M. Mateos, J. Miguel (2006)
Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myelomaHematological Oncology, 24
-
B. Samuels, J. Bitran (1995)
High-dose intravenous melphalan: a review.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 7
-
P. Selby, T. Mcelwain, A. Nandi, T. Perren, R. Powles, C. Tillyer, R. Osborne, M. Slevin, J. Malpas (1987)
Multiple myeloma treated with high dose intravenous melphalanBritish Journal of Haematology, 66
-
Andrew Belch, W. Shelley, D. Bergsagel, Kenneth Wilson, P. Klimo, D. White, Andrew Willan (1988)
A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients.British Journal of Cancer, 57
-
A. Palumbo, S. Bringhen, T. Caravita, E. Merla, V. Capparella, V. Callea, C. Cangialosi, M. Grasso, F. Rossini, M. Galli, L. Catalano, E. Zamagni, M. Petrucci, V. Stefano, M. Ceccarelli, M. Ambrosini, I. Avonto, P. Falco, G. Ciccone, A. Liberati, P. Musto, M. Boccadoro (2006)
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialThe Lancet, 367
-
B. Barlogie, R. Kyle, K. Anderson, P. Greipp, H. Lazarus, D. Hurd, J. Mccoy, D. Moore, S. Dakhil, K. Lanier, R. Chapman, J. Cromer, S. Salmon, B. Durie, J. Crowley (2006)
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 6
-
I. Lang, J. Windyga, A. Klukowska, J. Ilas, H. Schwarz, B. Reipert (2006)
Tracking Factor VIII-Specific Memory B Cells in Hemophilia A Patients with Factor VIII Inhibitors.Blood, 108
-
Á. Urbano-Ispizua, N. Schmitz, T. Witte, F. Frassoni, G. Rosti, H. Schrezenmeier, E. Gluckman, W. Friedrich, C. Cordonnier, G. Socié, A. Tyndall, D. Niethammer, P. Ljungman, A. Gratwohl, J. Apperley, D. Niederwieser, A. Bacigalupo, For Transplantation (2002)
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in EuropeBone Marrow Transplantation, 29
-
Gisele Sarosy, Brian Leyland-Jones, Patricia Soochan, B. Cheson (1988)
The systemic administration of intravenous melphalan.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 6 11
-
M. Attal, J. Harousseau, S. Leyvraz, C. Doyen, C. Hulin, L. Benboubker, I. Agha, J. Bourhis, L. Garderet, B. Pégourié, C. Dumontet, M. Renaud, L. Voillat, C. Berthou, G. Marit, M. Monconduit, D. Caillot, B. Grobois, H. Avet-Loiseau, P. Moreau, T. Facon (2006)
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.Blood, 108 10
-
J. Child, G. Morgan, F. Davies, R. Owen, S. Bell, K. Hawkins, Julia Brown, M. Drayson, P. Selby (2003)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.The New England journal of medicine, 348 19
-
J. Fermand, P. Ravaud, S. Chevret, M. Diviné, V. Leblond, C. Belanger, M. Macro, E. Pertuiset, F. Dreyfus, X. Mariette, C. Boccacio, J. Brouet (1998)
High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.Blood, 92 9
-
I. Majolino, M. Davoli, Ellen Carnevalli, A. Locasciulli, P. Bartolomeo, R. Scimé, P. Corradini, C. Selleri, F. Narni, M. Musso, M. Bregni, A. Olivieri, P. Fabritiis, Luigi Pogliani, Jorge Arbelaez, C. Ruscio, Andrea Institutions (2007)
Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myelomaLeukemia & Lymphoma, 48
-
Raman Desikan, B. Barlogie, J. Sawyer, D. Ayers, G. Tricot, A. Badros, M. Zangari, N. Munshi, E. Anaissie, D. Spoon, D. Siegel, S. Jagannath, D. Vesole, J. Epstein, J. Shaughnessy, A. Fassas, Seah Lim, Paula Roberson, J. Crowley (2000)
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.Blood, 95 12
-
M. Boccadoro, A. Palumbo, C. Argentino, A. Dominietto, R. Frieri, G. Avvisati, B. Comotti, V. Lauta, M. Liberati, F. Marmont, P. Musto, M. Tribalto, A. Pileri (1997)
Conventional induction treatments do not influence overall survival in multiple myelomaBritish Journal of Haematology, 96
-
J. Berenson, Hank Yang, K. Sadler, Supol Jarutirasarn, R. Vescio, R. Mapes, Matthew Purner, Shi-pyng Lee, Joanna Wilson, B. Morrison, Julian Adams, D. Schenkein, R. Swift (2006)
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 6
-
J. Bladé, L. Rosiñol, A. Sureda, J. Ribera, J. Díaz-Mediavilla, J. García-Laraña, V. Mateos, L. Palomera, J. Fernández-Calvo, J. Martí, P. Giraldo, F. Carbonell, M. Callis, J. Trujillo, S. Gardella, Jesús Moro, A. Bárez, A. Soler, L. Font, M. Fontanillas, J. San, Miguel On, Blanca, León (2005)
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.Blood, 106 12
-
• A brief review of frontline present therapeutic options for MM -
M. Petrucci, G. Avvisati, M. Tribalto, M. Cantonetti, P. Giovangrossi, F. Mandelli (1989)
Intermediate‐dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatmentEuropean Journal of Haematology, 42
-
J. Fermand, S. Katsahian, M. Diviné, V. Leblond, F. Dreyfus, M. Macro, B. Arnulf, B. Royer, X. Mariette, E. Pertuiset, C. Belanger, M. Janvier, S. Chevret, J. Brouet, P. Ravaud (2005)
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 36
-
K. Carlson, M. Hjorth, L. Knudsen (2005)
Toxicity in standard melphalan–prednisone therapy among myeloma patients with renal failure – a retrospective analysis and recommendations for dose adjustmentBritish Journal of Haematology, 128
-
R. Kyle, S. Rajkumar (2004)
Drug therapy: Multiple myelomaThe New England Journal of Medicine, 351
-
Author for correspondence Unit of Hematology and Stem Cell Transplantation, CROB -
(2007)
Bortezomib + ascorbic acid + melphalan upfront therapy -
• • An important study addressing the progresses of treatments during a large period in MM -
F. Cavallo, M. Ambrosini, C. Rus, M. Boccadoro, A. Palumbo (2007)
The treatment of the elderly multiple myeloma patientsLeukemia & Lymphoma, 48
-
J. Bladé, J. Miguel, M. Fontanillas, A. Alcalá, Jonathan Maldonado, Javier García-Conde, E. Conde, G. Conzález-Brito, M. Moro, M. Escudero, J. Trujillo, A. Pascual, C. Rozman, Jordi Estapé, E. Montserrat (1996)
Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 7
-
C. Shustik, A. Belch, S. Robinson, S. Rubin, S. Dolan, M. Kovacs, Kuljit Grewal, D. Walde, R. Barr, Jonathan Wilson, Kulwant Gill, L. Vickars, L. Rudinskas, D. Sicheri, K. Wilson, M. Djurfeldt, L. Shepherd, K. Ding, R. Meyer (2007)
A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7British Journal of Haematology, 136
-
J. Vela-Ojeda, M. García-Ruiz-Esparza, Y. Padilla-González, D. Gómez-Almaguer, C. Gutiérrez-Aguirre, D. Gómez-Rangel, A. Morales-Toquero, G. Ruiz-Delgado, J. Delgado-Lamas, G. Ruiz-Argüelles (2007)
Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalanAnnals of Hematology, 86
-
S. Singhal, J. Mehta, R. Desikan, D. Ayers, P. Roberson, Paul Eddlemon, N. Munshi, E. Anaissie, Carla Wilson, M. Dhodapkar, J. Zeldis, D. Siegel, J. Crowley, B. Barlogie (1999)
Antitumor activity of thalidomide in refractory multiple myeloma.The New England journal of medicine, 341 21
-
C. Walz, G. Metzgeroth, C. Haferlach, A. Schmitt-Graeff, A. Fabarius, V. Hagen, O. Prümmer, S. Rauh, R. Hehlmann, A. Hochhaus, N. Cross, A. Reiter (2007)
Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.Haematologica, 92 2
-
B. Barlogie, G. Tricot, E. Anaissie, J. Shaughnessy, E. Rasmussen, F. Rhee, A. Fassas, M. Zangari, K. Hollmig, M. Pineda‐Roman, Choon-kee Lee, G. Talamo, R. Thertulien, E. Kiwan, S. Krishna, M. Fox, J. Crowley (2006)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma.The New England journal of medicine, 354 10
-
N. Vogelzang (2006)
Treatment options in metastatic renal carcinoma: an embarrassment of riches.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 1
-
A. Gentles, Ash Alizadeh, Su-In Lee, J. Myklebust, C. Shachaf, Babak Shahbaba, Ronald Levy, Daphne Koller, S. Plevritis (2009)
A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients.Blood, 114 15
-
(2007)
Contemporary intravenous administration of bortezomib, melphalan and dexamethasone in previously treated myeloma patients -
A. Palumbo, S. Rajkumar (2009)
Treatment of newly diagnosed myelomaLeukemia, 23
-
S. Lenhoff, M. Hjorth, J. Westin, L. Brinch, Bengt Bäckström, K. Carlson, I. Christiansen, I. Dahl, P. Gimsing, J. Hammerström, H. Johnsen, G. Juliusson, O. Linder, U. Mellqvist, I. Nesthus, J. Nielsen, J. Tangen, I. Turesson (2006)
Impact of age on survival after intensive therapy for multiple myeloma: a population‐based study by the Nordic Myeloma Study GroupBritish Journal of Haematology, 133
-
M. Boccadoro, A. Palumbo, S. Bringhen, F. Merletti, G. Ciccone, L. Richiardi, C. Rus, A. Bertola, L. Giaccone, P. Omedè, P. Musto (2002)
Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.Haematologica, 87 8
-
W. Bensinger (2007)
Reduced intensity allogeneic stem cell transplantation in multiple myeloma.Frontiers in bioscience : a journal and virtual library, 12
-
M. Grazziutti, Li Dong, M. Miceli, S. Krishna, E. Kiwan, N. Syed, A. Fassas, F. Rhee, H. Klaus, B. Barlogie, E. Anaissie (2006)
Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive modelBone Marrow Transplantation, 38
-
M. Cavo, S. Rajkumar, S. Hayman, M. Lacy, A. Dispenzieri, S. Geyer, B. Kabat, S. Zeldenrust, Shaji Kumar, P. Greipp, R. Fonseca, J. Lust, S. Russell, R. Kyle, T. Witzig, M. Gertz (2005)
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.Blood, 106 13
-
• The role of age and renal failure in MM patients candidate to ASCT -
A. Carella, G. Beltrami, M. Corsetti, P. Scalzulli, A. Carella, P. Musto (2004)
A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity.Haematologica, 89 12
-
A. Anagnostopoulos, A. Alemán, G. Ayers, M. Donato, R. Champlin, D. Weber, R. Alexanian, S. Giralt (2004)
Comparison of high‐dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myelomaCancer, 100
-
L. Roy, J. Guilhot, T. Krahnke, A. Guerci-Bresler, B. Druker, R. Larson, S. O’Brien, Charlene So, G. Massimini, F. Guilhot (2006)
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.Blood, 108 5
-
D. Vesole, B. Barlogie, S. Jagannath, Bruce Cheson, G. Tricot, R. Alexanian, John Crowley (1994)
High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants.Blood, 84 3
-
A. Kühne, R. Kaiser, M. Schirmer, U. Heider, S. Muhlke, W. Niere, T. Overbeck, K. Hohloch, L. Trümper, O. Sezer, J. Brockmöller (2007)
Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalanPharmacogenetics and Genomics, 17
-
M. Vera‐Llonch, G. Oster, C. Ford, John Lu, S. Sonis (2007)
Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.The journal of supportive oncology, 5 5
-
T. Facon, J. Mary, J. Harousseau, F. Huguet, C. Berthou, B. Grosbois, B. Anglaret, A. Azzedine, P. Rodon, A. Peny (2006)
Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
-
P. Sonneveld, B. Holt, C. Segeren, E. Vellenga, A. Croockewit, Gregor Verhoe, J. Cornelissen, M. Schaafsma, M. Oers, P. Wijermans, P. Westveer, H. Lokhorst (2007)
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial.Haematologica, 92 7
-
D. Benson, P. Elder, T. Lin, W. Blum, S. Penza, B. Avalos, E. Copelan, S. Farag (2007)
High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma.Leukemia research, 31 8
-
A. Badros, B. Barlogie, E. Siegel, Jennifer Roberts, Candi Langmaid, M. Zangari, R. Desikan, M. Shaver, A. Fassas, S. McConnell, F. Muwalla, Y. Barri, E. Anaissie, N. Munshi, G. Tricot (2001)
Results of autologous stem cell transplant in multiple myeloma patients with renal failureBritish Journal of Haematology, 114
-
A. Palumbo, S. Bringhen, M. Petrucci, A. Falcone, A. Liberati, V. Lauta, M. Grasso, M. Montanaro, F. Pisani, T. Caravita, C. Cangialosi, P. Pregno, A. Nozza, E. Calabrese, F. Cavallo, P. Omedè, P. Musto, R. Foà, M. Boccadoro (2006)
A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m2 (MEL200) Versus Melphalan 100 mg/m2 (MEL100) in Newly Diagnosed Myeloma Patients.Blood, 110
-
B. Bruno, M. Rotta, F. Patriarca, N. Mordini, B. Allione, F. Carnevale-Schianca, L. Giaccone, R. Sorasio, P. Omedè, I. Baldi, S. Bringhen, M. Massaia, M. Aglietta, A. Levis, A. Gallamini, R. Fanin, A. Palumbo, R. Storb, G. Ciccone, M. Boccadoro (2007)
A comparison of allografting with autografting for newly diagnosed myeloma.The New England journal of medicine, 356 11
-
R. Popat, Cathy Williams, M. Cook, C. Craddock, S. Basu, C. Singer, Liz Odeh, N. Foot, H. Oakervee, J. Cavenagh (2006)
A Phase I/II Trial of Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma.Blood, 108
-
A. Dispenzieri, G. Wiseman, M. Lacy, M. Litzow, Peter Anderson, D. Gastineau, A. Tefferi, D. Inwards, Ivana Micallef, S. Ansell, L. Porrata, M. Elliott, John Lust, P. Greipp, S. Rajkumar, Rafael Fonseca, T. Witzig, C. Erlichman, Jeff Sloan, Morie Gertz (2005)
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaLeukemia, 19
-
M. Oken, D. Harrington, N. Abramson, R. Kyle, W. Knospe, J. Glick (1997)
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myelomaCancer, 79
-
S. Giralt, Ana Aleman, A. Anagnostopoulos, D. Weber, I. Khouri, P. Anderlini, J. Molldrem, N. Ueno, M. Donato, M. Korbling, J. Gajewski, R. Alexanian, R. Champlin (2002)
Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myelomaBone Marrow Transplantation, 30
-
J. Harousseau, N. Milpied, J. Laporte, P. Collombat, Thierry Facon, JD Tigaud, Philippe Casassus, F. Guilhot, N. Ifrah, C. Gandhour (1992)
Double-intensive therapy in high-risk multiple myeloma.Blood, 79 11
- Publisher
- Taylor & Francis
- Copyright
- © Informa UK Ltd
- ISSN
- 1744-7658
- eISSN
- 1354-3784
- DOI
- 10.1517/13543784.16.9.1467
- Publisher site
- See Article on Publisher Site
Abstract
The treatment of multiple myeloma has seen significant changes from the initial use of melphalan to the introduction of stem cell transplantation and, most recently, to the era of novel targeted agents. Melphalan still remains as a reference drug for combination regimens, including emerging newer therapeutic options, either used at a standard dose for initial or salvage treatments in patients who are not eligible for more intensive therapies, or in conjunction with new molecules within high-dose chemotherapy programs. In this review, the authors analyze old and novel regimens, including melphalan for the treatment of newly diagnosed or relapsed/resistant patients with multiple myeloma in the clinical settings of standard chemotherapy, as well as autologous or allogeneic stem cell transplantation.
Journal
Expert Opinion on Investigational Drugs – Taylor & Francis
Published: Sep 1, 2007
Keywords: bortezomib; lenalidomide; melphalan; multiple myeloma; stem cell transplantation; thalidomide